Search
- Nov 7, 2023
An AI expert describes how machine learning is changing drug development
Angela Holmes explains how her company uses computational power to help companies with drug development.
- Nov 7, 2023
The CEO of NKILT Therapeutics talks about using NK cells to target the HLA-G pathway
Raphaël Ognar discusses the results we have seen in the NK space over recent years.
- Nov 7, 2023
Tvardi Threrapeutics' CEO on targeting STAT3
Imran Alibhai describes how Tvardi is taking the approach of using a non-covalent inhibitor to prevent the activation of STAT3.
- Nov 7, 2023
Everything drug developers need to know about CPRIT oncology grants
CPRIT Deputy Executive Officer and General Counsel Kristen Doyle explains the details of this Texas cancer research funding program.
- Nov 7, 2023
UTMB's President discusses his institution, and comments on the chronic kidney disease field
Jochen Reiser talks about the reach of UTMB and the science happening in Galveston, and highlights immunology approaches to kidney disease.
- Nov 7, 2023
The director of Rice's Biotech Launchpad describes technologies that are being turned into companies
Omid Veiseh explains the idea behind Rice's Biotech Launchpad, describes the cytokine company Avenge Bio, and talks about other technologies